Medtronic recently acquired two medical device companies, Salient Surgical Technologies and PEAK Surgical, for a total of $645 million, according to company news releases.
Salient is a medical device company focused on the advanced energy category for haemostatic sealing of soft tissue and bone in various orthopedic, spine, abdominal and thoracic procedures. The $525 million acquisition will broaden Medtronic Surgical Technologies’ surgical products portfolio. Medtronic previously invested in Salient and currently holds an ownership stake in the company.
PEAK is a medical device company focused on the field of advanced surgical technology. PEAK’s product portfolio is based on its proprietary PlasmaBlade technology, which consists of a family of disposable cutting devices with proprietary insulation technology for use during electrosurgery. The acquisition was valued at $120 million. However, Medtronic also currently holds ownership stake in PEAK, and the transactional value is approximately $105 million.
Both transactions took place yesterday and are subject to governmental and regulatory review. The companies will operate under separate entities until the transaction is cleared.
Related Articles on Medtronic:
Medtronic Releases CD HORIZON SOLERA Spinal system
Medtronic Launches New Spinal System
Medtronic CEO Omar Ishrak Defends Medtronic, Infuse
Salient is a medical device company focused on the advanced energy category for haemostatic sealing of soft tissue and bone in various orthopedic, spine, abdominal and thoracic procedures. The $525 million acquisition will broaden Medtronic Surgical Technologies’ surgical products portfolio. Medtronic previously invested in Salient and currently holds an ownership stake in the company.
PEAK is a medical device company focused on the field of advanced surgical technology. PEAK’s product portfolio is based on its proprietary PlasmaBlade technology, which consists of a family of disposable cutting devices with proprietary insulation technology for use during electrosurgery. The acquisition was valued at $120 million. However, Medtronic also currently holds ownership stake in PEAK, and the transactional value is approximately $105 million.
Both transactions took place yesterday and are subject to governmental and regulatory review. The companies will operate under separate entities until the transaction is cleared.
Related Articles on Medtronic:
Medtronic Releases CD HORIZON SOLERA Spinal system
Medtronic Launches New Spinal System
Medtronic CEO Omar Ishrak Defends Medtronic, Infuse